These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 16415132)

  • 1. Chemoembolization in patients at high risk: results and complications.
    Kiely JM; Rilling WS; Touzios JG; Hieb RA; Franco J; Saeian K; Quebbeman EJ; Pitt HA
    J Vasc Interv Radiol; 2006 Jan; 17(1):47-53. PubMed ID: 16415132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk.
    Kothary N; Weintraub JL; Susman J; Rundback JH
    J Vasc Interv Radiol; 2007 Dec; 18(12):1517-26; quiz 1527. PubMed ID: 18057286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.
    Kim KM; Kim JH; Park IS; Ko GY; Yoon HK; Sung KB; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Gastroenterol Hepatol; 2009 May; 24(5):806-14. PubMed ID: 19207681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis.
    Kim JH; Yoon HK; Kim SY; Kim KM; Ko GY; Gwon DI; Sung KB
    Aliment Pharmacol Ther; 2009 Jun; 29(12):1291-8. PubMed ID: 19392861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma.
    Brown DB; Fundakowski CE; Lisker-Melman M; Crippin JS; Pilgram TK; Chapman W; Darcy MD
    J Vasc Interv Radiol; 2004 Nov; 15(11):1209-18. PubMed ID: 15525739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients.
    Yuen MF; Chan AO; Wong BC; Hui CK; Ooi GC; Tso WK; Yuan HJ; Wong DK; Lai CL
    Am J Gastroenterol; 2003 May; 98(5):1181-5. PubMed ID: 12809846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparison of patients with hepatocellular carcinoma between a short-term (less than 6 months) survival group and a long-term (over 24 months) survival group after treatment with transcatheter arterial chemoembolization].
    Kang IK; Kim SW; Hahn SH; Cho SC; Gham CW; Lee DH
    Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):189-200. PubMed ID: 12499805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.
    Grieco A; Marcoccia S; Miele L; Marmiroli L; Caminiti G; Ragazzoni E; Cotroneo AR; Cefaro GA; Rapaccini GL; Gasbarrini G
    Hepatogastroenterology; 2003; 50(49):207-12. PubMed ID: 12630024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization.
    Yau T; Yao TJ; Chan P; Epstein RJ; Ng KK; Chok SH; Cheung TT; Fan ST; Poon RT
    Cancer; 2009 Dec; 115(23):5507-15. PubMed ID: 19701904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey.
    Huo T; Huang YH; Wu JC; Chiang JH; Lee PC; Chang FY; Lee SD
    Aliment Pharmacol Ther; 2004 Jun; 19(12):1301-8. PubMed ID: 15191512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection.
    Shim JH; Kim KM; Lee YJ; Ko GY; Yoon HK; Sung KB; Park KM; Lee SG; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    Ann Surg Oncol; 2010 Mar; 17(3):869-77. PubMed ID: 20033326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis.
    Pietrosi G; Miraglia R; Luca A; Vizzini GB; Fili' D; Riccardo V; D'Antoni A; Petridis I; Maruzzelli L; Biondo D; Gridelli B
    J Vasc Interv Radiol; 2009 Jul; 20(7):896-902. PubMed ID: 19497762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.
    Park KW; Park JW; Choi JI; Kim TH; Kim SH; Park HS; Lee WJ; Park SJ; Hong EK; Kim CM
    J Gastroenterol Hepatol; 2008 Mar; 23(3):467-73. PubMed ID: 17764529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
    Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
    J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term results of interventional treatment of large unresectable hepatocellular carcinoma (HCC): significant survival benefit from combined transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) compared to TACE monotherapy].
    Lubienski A; Bitsch RG; Schemmer P; Grenacher L; Düx M; Kauffmann GW
    Rofo; 2004 Dec; 176(12):1794-802. PubMed ID: 15573291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma.
    Li M; Lu C; Cheng J; Zhang J; Cao C; Xu J; Xu J; Pan H; Zhong B; Tucker S; Wang D
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1437-44. PubMed ID: 19486255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study.
    Lee HS; Kim JS; Choi IJ; Chung JW; Park JH; Kim CY
    Cancer; 1997 Jun; 79(11):2087-94. PubMed ID: 9179054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors.
    Lu W; Li Y; He X; Chen Y
    Hepatogastroenterology; 2003; 50(54):2079-83. PubMed ID: 14696468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.